Business Description
Amneal Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US03168L1052
Share Class Description:
FRA:2DT: Ordinary Shares - Class ADescription
Amneal Pharmaceuticals Inc is a global pharmaceutical company operating primarily in the U.S., India, and Ireland. With three reportable segments; Generics, Specialty, and AvKARE - It develop, manufacture, and distribute a diverse portfolio of essential medicines. The Generics segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.03 | |||||
| Equity-to-Asset | -0.03 | |||||
| Debt-to-Equity | -28.31 | |||||
| Debt-to-EBITDA | 7.34 | |||||
| Interest Coverage | 1.09 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 1.23 | |||||
| Beneish M-Score | -2.99 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 0.5 | |||||
| 3-Year EBITDA Growth Rate | -0.7 | |||||
| 3-Year FCF Growth Rate | -9.3 | |||||
| 3-Year Book Growth Rate | -68.4 | |||||
| Future 3-5Y Total Revenue Growth Rate | 7.05 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.49 | |||||
| 9-Day RSI | 39.79 | |||||
| 14-Day RSI | 42.73 | |||||
| 6-1 Month Momentum % | 21.6 | |||||
| 12-1 Month Momentum % | 59 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.38 | |||||
| Quick Ratio | 0.84 | |||||
| Cash Ratio | 0.07 | |||||
| Days Inventory | 122.18 | |||||
| Days Sales Outstanding | 95.09 | |||||
| Days Payable | 39.21 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -27.6 | |||||
| Shareholder Yield % | 5.09 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 35.35 | |||||
| Operating Margin % | 10.4 | |||||
| Net Margin % | -6.88 | |||||
| FCF Margin % | 8.49 | |||||
| ROE % | -678.04 | |||||
| ROA % | -5.24 | |||||
| ROIC % | 11.4 | |||||
| ROC (Joel Greenblatt) % | 10.81 | |||||
| ROCE % | 5.15 | |||||
| Years of Profitability over Past 10-Year | 4 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 10.58 | |||||
| PE Ratio without NRI | 13.08 | |||||
| Price-to-Owner-Earnings | 230.88 | |||||
| PEG Ratio | 0.68 | |||||
| PS Ratio | 0.86 | |||||
| Price-to-Free-Cash-Flow | 9.5 | |||||
| Price-to-Operating-Cash-Flow | 6.98 | |||||
| EV-to-EBIT | 37.83 | |||||
| EV-to-EBITDA | 14 | |||||
| EV-to-Revenue | 1.88 | |||||
| EV-to-FCF | 22 | |||||
| Price-to-Projected-FCF | 1.64 | |||||
| Earnings Yield (Greenblatt) % | 2.64 | |||||
| FCF Yield % | 9.42 | |||||
| Forward Rate of Return (Yacktman) % | 10.63 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Amneal Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 2,457.106 | ||
| EPS (TTM) (€) | -0.624 | ||
| Beta | 1.4 | ||
| Volatility % | 46.06 | ||
| 14-Day RSI | 42.73 | ||
| 14-Day ATR (€) | 0.237683 | ||
| 20-Day SMA (€) | 7.57 | ||
| 12-1 Month Momentum % | 59 | ||
| 52-Week Range (€) | 4.74 - 8.55 | ||
| Shares Outstanding (Mil) | 309.84 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Amneal Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Amneal Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Amneal Pharmaceuticals Inc Frequently Asked Questions
What is Amneal Pharmaceuticals Inc(FRA:2DT)'s stock price today?
The current price of FRA:2DT is €7.25. The 52 week high of FRA:2DT is €8.55 and 52 week low is €4.74.
When is next earnings date of Amneal Pharmaceuticals Inc(FRA:2DT)?
The next earnings date of Amneal Pharmaceuticals Inc(FRA:2DT) is 2025-02-28 Est..
Does Amneal Pharmaceuticals Inc(FRA:2DT) pay dividends? If so, how much?
Amneal Pharmaceuticals Inc(FRA:2DT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers